EP2720677A2 - Utilisation de substances agissant sur l'igf-1 et/ou l'igf-1r pour leur activite anti-age - Google Patents
Utilisation de substances agissant sur l'igf-1 et/ou l'igf-1r pour leur activite anti-ageInfo
- Publication number
- EP2720677A2 EP2720677A2 EP12738512.8A EP12738512A EP2720677A2 EP 2720677 A2 EP2720677 A2 EP 2720677A2 EP 12738512 A EP12738512 A EP 12738512A EP 2720677 A2 EP2720677 A2 EP 2720677A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- igf
- skin
- active ingredient
- substance
- acting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 title claims abstract description 48
- 230000003712 anti-aging effect Effects 0.000 title description 3
- 101150088952 IGF1 gene Proteins 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims abstract description 92
- 210000003491 skin Anatomy 0.000 claims abstract description 54
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract description 44
- 239000002537 cosmetic Substances 0.000 claims abstract description 29
- 230000032683 aging Effects 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 22
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract description 13
- 230000008569 process Effects 0.000 claims abstract description 13
- 210000004927 skin cell Anatomy 0.000 claims abstract description 8
- 230000000699 topical effect Effects 0.000 claims abstract description 4
- 241000192351 [Candida] oleophila Species 0.000 claims description 18
- 230000037303 wrinkles Effects 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 15
- 210000002950 fibroblast Anatomy 0.000 claims description 15
- 241001539893 Hanseniaspora opuntiae Species 0.000 claims description 14
- 244000286779 Hansenula anomala Species 0.000 claims description 12
- 230000004888 barrier function Effects 0.000 claims description 11
- 230000026731 phosphorylation Effects 0.000 claims description 10
- 238000006366 phosphorylation reaction Methods 0.000 claims description 10
- 241000196324 Embryophyta Species 0.000 claims description 9
- 235000006089 Phaseolus angularis Nutrition 0.000 claims description 6
- 240000007098 Vigna angularis Species 0.000 claims description 6
- 235000010711 Vigna angularis Nutrition 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 230000002255 enzymatic effect Effects 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 235000011430 Malus pumila Nutrition 0.000 claims description 5
- 235000015103 Malus silvestris Nutrition 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 4
- 240000006859 Jasminum officinale Species 0.000 claims description 4
- 235000010254 Jasminum officinale Nutrition 0.000 claims description 4
- 240000000249 Morus alba Species 0.000 claims description 4
- 235000008708 Morus alba Nutrition 0.000 claims description 4
- 244000021273 Peumus boldus Species 0.000 claims description 4
- 235000012550 Pimpinella anisum Nutrition 0.000 claims description 4
- 240000004760 Pimpinella anisum Species 0.000 claims description 4
- 244000144725 Amygdalus communis Species 0.000 claims description 3
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 3
- 244000020551 Helianthus annuus Species 0.000 claims description 3
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 3
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 3
- 235000017879 Nasturtium officinale Nutrition 0.000 claims description 3
- 240000005407 Nasturtium officinale Species 0.000 claims description 3
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- 235000007238 Secale cereale Nutrition 0.000 claims description 3
- 210000005175 epidermal keratinocyte Anatomy 0.000 claims description 3
- 235000005274 Annona squamosa Nutrition 0.000 claims description 2
- 244000028821 Annona squamosa Species 0.000 claims description 2
- OWNRRUFOJXFKCU-UHFFFAOYSA-N Bromadiolone Chemical compound C=1C=C(C=2C=CC(Br)=CC=2)C=CC=1C(O)CC(C=1C(OC2=CC=CC=C2C=1O)=O)C1=CC=CC=C1 OWNRRUFOJXFKCU-UHFFFAOYSA-N 0.000 claims description 2
- 241001070941 Castanea Species 0.000 claims description 2
- 235000014036 Castanea Nutrition 0.000 claims description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 2
- 244000183685 Citrus aurantium Species 0.000 claims description 2
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 235000014683 Hansenula anomala Nutrition 0.000 claims description 2
- 235000004412 Jasminum grandiflorum Nutrition 0.000 claims description 2
- 241000408747 Lepomis gibbosus Species 0.000 claims description 2
- 235000004431 Linum usitatissimum Nutrition 0.000 claims description 2
- 235000010649 Lupinus albus Nutrition 0.000 claims description 2
- 240000000894 Lupinus albus Species 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 2
- 235000015933 Peumus boldus Nutrition 0.000 claims description 2
- 241000235070 Saccharomyces Species 0.000 claims description 2
- 241001092387 Spiraea Species 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 244000098338 Triticum aestivum Species 0.000 claims description 2
- 235000004424 Tropaeolum majus Nutrition 0.000 claims description 2
- 240000001260 Tropaeolum majus Species 0.000 claims description 2
- 235000017803 cinnamon Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000009569 green tea Nutrition 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 239000001909 pimpinella anisum Substances 0.000 claims description 2
- 235000020236 pumpkin seed Nutrition 0.000 claims description 2
- 235000009566 rice Nutrition 0.000 claims description 2
- 229920002477 rna polymer Polymers 0.000 claims description 2
- 244000070406 Malus silvestris Species 0.000 claims 3
- 108010071003 insulin-related factor Proteins 0.000 claims 3
- 240000007594 Oryza sativa Species 0.000 claims 2
- 241001278097 Salix alba Species 0.000 claims 2
- 244000082988 Secale cereale Species 0.000 claims 2
- 241000282836 Camelus dromedarius Species 0.000 claims 1
- 235000014037 Castanea sativa Nutrition 0.000 claims 1
- 240000007857 Castanea sativa Species 0.000 claims 1
- 240000001980 Cucurbita pepo Species 0.000 claims 1
- 235000009852 Cucurbita pepo Nutrition 0.000 claims 1
- 235000016622 Filipendula ulmaria Nutrition 0.000 claims 1
- 244000061544 Filipendula vulgaris Species 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 235000015164 Iris germanica var. florentina Nutrition 0.000 claims 1
- 240000006240 Linum usitatissimum Species 0.000 claims 1
- 235000017011 Mandorlo dulce Nutrition 0.000 claims 1
- 244000076313 Mandorlo dulce Species 0.000 claims 1
- 241001479543 Mentha x piperita Species 0.000 claims 1
- 235000004426 flaxseed Nutrition 0.000 claims 1
- 244000023249 iris florentino Species 0.000 claims 1
- 239000001771 mentha piperita Substances 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 102000004584 Somatomedin Receptors Human genes 0.000 abstract description 24
- 108010017622 Somatomedin Receptors Proteins 0.000 abstract description 24
- 239000000902 placebo Substances 0.000 description 36
- 229940068196 placebo Drugs 0.000 description 36
- 206010040954 Skin wrinkling Diseases 0.000 description 23
- 230000000694 effects Effects 0.000 description 20
- 238000011156 evaluation Methods 0.000 description 19
- 238000005259 measurement Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000344 soap Substances 0.000 description 12
- 230000007423 decrease Effects 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 230000036571 hydration Effects 0.000 description 10
- 238000006703 hydration reaction Methods 0.000 description 10
- 230000000007 visual effect Effects 0.000 description 10
- 230000007071 enzymatic hydrolysis Effects 0.000 description 9
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 9
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 238000005063 solubilization Methods 0.000 description 7
- 230000007928 solubilization Effects 0.000 description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 6
- 244000309466 calf Species 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 229930182478 glucoside Natural products 0.000 description 5
- 150000008131 glucosides Chemical class 0.000 description 5
- 238000001728 nano-filtration Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000001223 reverse osmosis Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 230000004075 alteration Effects 0.000 description 4
- 230000001153 anti-wrinkle effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000010908 decantation Methods 0.000 description 4
- 229960000735 docosanol Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000009499 grossing Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 229940100554 isononyl isononanoate Drugs 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N n-octadecyl alcohol Natural products CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 230000003746 surface roughness Effects 0.000 description 4
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 241000220225 Malus Species 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940081733 cetearyl alcohol Drugs 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 229940031674 laureth-7 Drugs 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229920005573 silicon-containing polymer Polymers 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- DHFUFHYLYSCIJY-WSGIOKLISA-N CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DHFUFHYLYSCIJY-WSGIOKLISA-N 0.000 description 2
- 235000009967 Erodium cicutarium Nutrition 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 241000209056 Secale Species 0.000 description 2
- 125000005250 alkyl acrylate group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 229940074047 glyceryl cocoate Drugs 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- IXUATGFEVCPOOD-UHFFFAOYSA-N 2,3-dihydroxypropyl octadecanoate;octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO IXUATGFEVCPOOD-UHFFFAOYSA-N 0.000 description 1
- 102100022681 40S ribosomal protein S27 Human genes 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101000678466 Homo sapiens 40S ribosomal protein S27 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000208202 Linaceae Species 0.000 description 1
- 241000208204 Linum Species 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000899950 Salix glauca Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- -1 dibutyl lauryl Chemical group 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229940087073 glycol palmitate Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
Definitions
- the present invention relates to the use in a cosmetic composition of a particular substance as a cosmetic active ingredient intended to prevent and / or combat the aging of the skin.
- the invention also relates to a cosmetic process for preventing or combating cutaneous aging, comprising the application to the skin of a composition comprising at least this substance as active principle.
- the objective of the present invention is to propose products capable of effectively combating cutaneous aging and limiting the appearance of the adverse effects that result therefrom.
- the aging of the skin results from alterations that occur spontaneously over time or that are induced by various external factors.
- Other factors may also participate such as the alteration of cellular communications, endocrine aging during menopause or the mechanical factors of Earth's gravity. Numerous molecular and cellular phenomena intervene in the aging of the cutaneous tissue. Some of the observed transformations are the result of a change in the body's natural secretion of hormones and growth factors.
- the present invention aims to use a substance that can act on the mechanisms involved in the aging of the cutaneous tissue, in particular on the mechanisms able to combat the decline in activity of aging cells of the cutaneous tissue and to wake up biologically skin cells and protect the skin barrier function.
- the invention relates to the use as a cosmetic active ingredient in a cosmetic composition, at least one substance acting on the IGF-1 ("insulin-like growth factor") and / or on IGF-1R (insulin-like growth factor receptor) of cutaneous cells.
- IGF-1 insulin-like growth factor
- IGF-1R insulin-like growth factor receptor
- the subject of the invention is also a cosmetic process for preventing or combating cutaneous aging, comprising the topical application to the skin of a composition containing at least one substance acting on IGF-1 and / or on IGF. -lR cutaneous cells.
- the use of a substance acting on IGF-1 and / or on IGF-IR in particular makes it possible to reduce wrinkles and fine lines and to improve the cutaneous barrier function of aged skin.
- the object of the invention is the use in a cosmetic composition of an effective amount of at least one substance acting on IGF-1 and / or IGF-1R of cutaneous cells as a cosmetic active ingredient for prevent or fight against aging skin.
- Insulin-like growth factors particularly IGF-1 and I & F-2, are peptide growth factors with a chemical structure similar to that of insulin. . These growth factors are predominantly secreted by the liver, but IGF-1 is also secreted by dermal fibroblasts.
- IGF-1R insulin-like growth factor receptor
- IGF-1R The insulin-like growth factor receptor, IGF-1R is a transmembrane receptor comprising two alpha subunits and two beta subunits. It has an ATP site (Adenosine Triphosphate) which is used during its activation by phosphorylation.
- IGF-IR is expressed in human skin at basal keratinocytes and is activated by IGF-1 secreted by dermal fibroblasts by a phosphorylation mechanism.
- Phosphorylated IGF-IR is the activated form of IGF-IR.
- the integrity of the skin's functionality is dependent on the synergistic interaction between IGF-1 of the dermal fibroblasts and the phosphorylated I ⁇ 9F-1R of the epidermal keratinocytes.
- IGF-1 of the dermal fibroblasts decreases, therefore the expression of phosphorylation of IGF-1R in keratinocytes also decreases, which leads to an alteration of the cutaneous barrier function and the appearance parameters related to aging of the skin such as wrinkles, loss of elasticity and significant skin fineness.
- the use according to the invention of a substance acting on IGF-1 and / or I ⁇ 9F-1R makes it possible to prevent and / or to fight against the decrease in the level of IGF-1 and increase the phosphorylation of IGF-1R in skin cells and thus prevent and / or fight against aging of the skin.
- the substance acting on IGF-1 or IGF-IR is a substance:
- mRNA messenger ribonucleic acids
- This substance is preferably obtained from at least one plant or at least one yeast.
- the substance is derived from at least one plant, it is a substance acting on IGF-1 and / or IGF-IR derived from at least one plant selected from bitter orange (Cifrus auranfium amara), sweet almond (Prunus amygdalus du / cis), sweet white lupine (Lupinus a / bus), sunflower (Helianfhus annuus), white willow (Salix a / ba), rice (Oryza safiva) , apple ⁇ Py rus malus), green anise (Pimpinella anisum), wheat germ (Trificum vu / gare), adzuki (Vigna angularis), peppermint (Menfha piperifd), rye (Secale cerea (e) green tea (Cameia lia sinensis), meadow queen (Spiraea u / maria), nasturtium (Tropaeo / um majus), pumpkin seeds
- the substance is derived from at least one yeast
- it is a substance acting on IGF-I and / or I ⁇ 9F-1R derived from at least one yeast selected from Saccharomyces cerevisae, Pichia anomala, Candida oleophila, Hanseniaspora opuntiae and Torulospora delruekii.
- it is a hydrolyzate, in particular an enzymatic hydrolyzate of at least one plant or at least one yeast.
- the substance acting on IGF-1 and / or IGF-IR is obtained from a vegetable raw material or a yeast by a process comprising at least one step of solubilizing the raw material and a step enzymatic hydrolysis.
- the substance acting on the IGF-1 and / or the IGF-1R of the cutaneous cells can be selected by a test carried out on cutaneous cell cultures comprising the following steps:
- Substances capable of acting on IGF-1 and / or on I-9F-1R are intended to be incorporated in cosmetic compositions, in particular in a proportion of 0.01 to 20%.
- composition may be in the form of creams, emulsions, oil-in-water, water-in-oil or multiple emulsions, solutions, suspensions or powders.
- the administration of the composition is preferably carried out topically.
- the invention also specifically relates to a cosmetic process for preventing and / or combating cutaneous aging, comprising the topical application to the skin of a composition comprising at least one substance acting on IGF-I and / or IGF skin cells as a cosmetic active ingredient.
- a useful substance according to the invention can be obtained by the implementation of a process comprising at least one solubilization step of Vigna angularis (adzuki) and at least one enzymatic hydrolysis step.
- the method of obtaining preferably consists in the succession of the following steps:
- a useful substance according to the invention can be obtained by carrying out a process comprising at least one solubilization step of the Candida oleophila ferment and at least one enzymatic hydrolysis step.
- the method of obtaining preferably consists in the succession of the following steps:
- a useful substance according to the invention can be obtained by carrying out a process comprising at least one step of solubilizing the Hanseniaspora opuntiae ferment and at least one enzymatic hydrolysis step.
- the method of obtaining preferably consists in the succession of the following steps:
- a useful substance according to the invention can be obtained by carrying out a process comprising at least one solubilization step of the Torulospora delbruekii ferment and at least one enzymatic hydrolysis step.
- the method of obtaining preferably consists in the succession of the following steps:
- compositions are obtained by mixing the various components.
- the quantities indicated are given as a percentage of weight.
- Cetearyl alcohol / Ceteraryl glucoside 2.0%
- the objective of this study is to evaluate the ability of the active ingredients of the examples of point I. to increase the expression of the mRNAs coding for IGF-1 in cultures of young and old human fibroblasts.
- the operating protocol is as follows. At 0, the aged young fibroblasts are inoculated in a suitable culture medium and the cells are then incubated at 37 ° C.
- the cell culture medium (aged) is removed and replaced by medium containing the active ingredients:
- the cells are then incubated for 6 hours at 37 ° C.
- the cells are recovered (for IGF-1 assay) and the total RNA extracted.
- the RNAs are reverse transcripts and the complementary DNAs obtained are analyzed by the quantitative PCR technique.
- the mRNAs of the ribosomal protein S27, an internal reference control, are also analyzed in parallel with the IGF-1 mRNAs.
- the objective of this study is to evaluate the ability of active ingredients of the examples of point I. to increase the synthesis of I & F-1 proteins on human skin explants.
- the operating protocol is as follows. At OG, punches 8mm in diameter are made from human plasty from young and old donors and maintained in survival in culture medium.
- the culture medium is removed and replaced with culture medium containing the active ingredients.
- the objective of this study is to evaluate the ability of active ingredients of the examples of point I. to increase the expression of phosphorylation of IGF-1R on human skin explants.
- the operating protocol is as follows.
- punches 8mm in diameter are made from human plasty from young and old donors and maintained in survival in culture medium.
- the culture medium is removed and replaced with culture medium containing the active ingredients.
- Immunohistological staining of phosphorylated IGF-1R is performed on the skin sections.
- the visualization is performed on a microscope coupled to an image analysis system. Quantitative image analysis was performed using Matlab® software.
- the objective of this study is to quantify in vivo, on volunteers, the restructuring effect at the calves of an active ingredient of Example 1.2 formulated to 3% gel-emulsified in comparison with a placebo.
- compositions used are the following:
- the measurement zones are as follows:
- the measurements of the PIE were made using a Tewameter ® .
- This apparatus is equipped with a probe which measures the gradient of water vapor that is placed between the skin surface and the ambient air.
- a decrease of the PIE is characteristic of an improvement of the barrier function of the skin.
- I & F-1, IGF-1R in particular an active ingredient derived from Candida oleophila as presented in point 1.2, makes it possible to reduce the loss of water in the skin thus making it possible to restore the barrier effect of previously altered skin.
- the measurements were made using a Cornecometer ® .
- This device is equipped with a probe that measures quantitatively and directly, the electrical capacitance of the skin, that is to say the capacity of the intercellular water of the stratum corneum to drive the electrons. This measurement is directly related to the state of hydration of the skin.
- An increase in the level of hydration is representative of an improvement in the hydration state of the skin.
- IGF-1R formulated with 3% emulsified gel improves the hydration of a skin. previously impaired at SLS.
- IGF-1R an active ingredient derived from Candida oleophila as presented in point 1.2, therefore makes it possible to increase the hydration of the skin.
- the acquisitions (corresponding to horizontal sections of the skin) were carried out using a confocal microscope on volunteers at the level of the stratum corneum, after local application of fluorescein.
- the recovered images were then visually assessed by a trained panel consisting of 4 people using a score scale including 4
- An increase of the stage is characteristic of an improvement of the surface state of the skin and thus of an improvement of the cellular organization of the superficial layer of the skin.
- IGF-1R formulated at 3% emulsified gel promotes an improvement in the appearance of skin area of 15.6%.
- I & F-1, IGF-1R an active ingredient acting on I & F-1, IGF-1R, in particular an active ingredient derived from Candida oleophila as presented in point 1.2, thus makes it possible to restore the cellular organization of the superficial layer of the skin.
- Drowning of the state of dryness on the calves was performed blind under shading conditions standardized by a trained expert.
- Stage 2 small white particles of dry skin, whitening of furrows and skin folds.
- a decrease in the stage is characteristic of a reduction of the dryness of the skin.
- an active ingredient acting on I & F-1, I & F-Ik in particular an active ingredient derived from Candida oleophila as presented in point 1.2 formulated at 3% gel-emulsified and in comparison to placebo:
- the objective of this study is to quantify in vivo, on volunteers, the anti-aging effect of an active ingredient of Example 1.2 formulated at 3% gel-emulsified in comparison with a placebo.
- compositions used are the following:
- Silicone polymer fingerprints were made before and after use of the products in the cheeks.
- volume acquisitions of these fingerprints were made using a fringe projection device dedicated to the 3D measurement of the relief of the fingerprints.
- the parameters that can be studied are roughness parameters in 3D:
- ⁇ Sa arithmetic average of surface roughness
- a decrease in these different parameters is characteristic of a smoothing of the studied surface.
- I & F-1, IGF-1R an active ingredient acting on I & F-1, IGF-1R, in particular an active ingredient derived from Candida oleophila as presented in point 1.2, thus makes it possible to smooth the cutaneous relief.
- Silicone polymer footprints were made before and after use of the products on the crow's feet.
- a decrease in these different parameters is characteristic of a smoothing of the relief of the studied surface and a reduction of wrinkles.
- Silicone polymer fingerprints were made before and after use of the products in the cheeks.
- volume acquisitions of these fingerprints were made using a fringe projection device dedicated to the 3D measurement of the relief of the fingerprints.
- the parameters that can be studied are roughness parameters in 3D:
- the volume of the wrinkle is studied by a parameter of volume: negative volume ie volume lower than the surface of the skin
- a decrease in these different parameters is characteristic of a smoothing of the studied surface.
- Negative volume -11.1% -19.6% It is found that under the conditions of this study, after 28 days of twice-daily application, compared to placebo, an active ingredient acting on I-F, IGF-1R formulated at 3% in emulsified gel improves the cutaneous relief at the level of the crow's feet by reducing the parameters of 3D roughness and negative volume. This effect continues after 56 days of treatment.
- a jury composed of 3 people evaluated the stage of crow's feet wrinkles of each photo on a scale of previously defined score.
- the score scale was established from a selection of photos of different grades of wrinkles observed
- IGF-1R formulated with 3% emulsified gel reduces the average wrinkle stage of the crow's foot area after blinded visual evaluation on photographs.
- the visual scouring of the crow's feet stage was performed blindly by two experts previously trained under standardized light conditions, elongated volunteer and closed eyes.
- the scale of scores used is the same as that used for visual scoring on photographs.
- an active ingredient acting on I & F-1, I & F-1, in particular an active ingredient derived from Candida oleophila as presented at point 1.2 formulated at 3% in emulsion allows to smooth the cutaneous microrelief and presents an anti-wrinkle effect at once quantifiable and visually perceptible directly on volunteers.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1155401A FR2976490B1 (fr) | 2011-06-20 | 2011-06-20 | Utilisation de substances agissant sur l'igf-1 et/ou l'igf-1r pour leur activite anti-age |
PCT/FR2012/051388 WO2012175868A2 (fr) | 2011-06-20 | 2012-06-20 | Utilisation de substances agissant sur l'igf-1 et/ou l'igf-1r pour leur activite anti-age |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2720677A2 true EP2720677A2 (fr) | 2014-04-23 |
EP2720677B1 EP2720677B1 (fr) | 2020-12-02 |
Family
ID=46579173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12738512.8A Active EP2720677B1 (fr) | 2011-06-20 | 2012-06-20 | Utilisation de substances agissant sur l'igf-1 et/ou l'igf-1r pour leur activite anti-age |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2720677B1 (fr) |
FR (1) | FR2976490B1 (fr) |
WO (1) | WO2012175868A2 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170112737A1 (en) * | 2014-03-18 | 2017-04-27 | Greenpharma | Cosmetics and pharmaceutical applications of gallic acid and gallic acid derivatives |
US20170128357A1 (en) | 2015-11-06 | 2017-05-11 | Johnson & Johnson Consumer Inc. | Topical gel cream composition |
US20170172913A1 (en) | 2015-12-17 | 2017-06-22 | Johnson & Johnson Consumer Inc. | Topical Compositions Comprising Pichia Anomala and Chicory Root Extracts |
US10543240B2 (en) | 2016-12-12 | 2020-01-28 | Johnson & Johnson Consumer Inc. | Topical composition containing glycerin and yeast extract |
US10206870B2 (en) | 2016-12-12 | 2019-02-19 | Johnson & Johnson Consumer Inc. | Topical composition containing glycerin and yeast extract |
US11166997B2 (en) | 2018-07-27 | 2021-11-09 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
WO2020021481A1 (fr) | 2018-07-27 | 2020-01-30 | Johnson & Johnson Vision Care, Inc. | Compositions et méthodes de traitement de l'œil |
CA3106898A1 (fr) | 2018-07-27 | 2020-01-30 | Johnson & Johnson Surgical Vision, Inc. | Compositions et methodes de traitement de l'oeil |
AU2019203692A1 (en) | 2018-08-30 | 2020-03-19 | Johnson & Johnson Consumer Inc. | Topical composition containing glycerin and yeast extract |
US11110051B2 (en) | 2018-08-30 | 2021-09-07 | Johnson & Johnson Consumer Inc. | Topical compositions comprising Pichia anomala and n-acetyl glucosamine |
US20200069562A1 (en) | 2018-08-30 | 2020-03-05 | Johnson & Johnson Consumer Inc. | Topical compositions comprising pichia anomala and a soy product |
US11045416B2 (en) | 2018-08-30 | 2021-06-29 | Johnson & Johnson Consumer Inc. | Topical compositions comprising Pichia anomala and retinol |
CN110317739B (zh) * | 2019-07-18 | 2021-06-01 | 海南大学 | 一株仙人掌有孢汉逊酵母菌株及其分离方法和应用 |
US11969451B2 (en) | 2019-11-19 | 2024-04-30 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
CN111743802B (zh) * | 2020-07-28 | 2022-02-25 | 广州鹰远生物科技有限公司 | 一种增加肌肤弹性的组合物及其应用 |
EP4043005B1 (fr) * | 2021-02-12 | 2023-12-20 | Chanel Parfums Beauté | Composition cosmétique comprenant un hydrolysat de levure |
AU2023236843A1 (en) * | 2022-03-16 | 2024-10-03 | Lubrizol Advanced Materials, Inc. | Protein hydrolysates of azuki beans and cosmetic uses thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2779058B1 (fr) * | 1998-05-29 | 2003-02-21 | Dior Christian Parfums | Utilisation d'au moins une saponine ou un sapogenol cosmetiquement acceptable, comme agent cosmetique destine a augmenter la quantite de collagene iv dans la jonction dermo-epidermique |
FR2797186B1 (fr) * | 1999-08-02 | 2003-07-04 | Silab Sa | Procede d'extraction d'un principe actif a partir de levures, notamment pour le traitement des rides, principe actif obtenu, compositions cosmetiques et traitement adaptes |
FR2815539B1 (fr) * | 2000-10-23 | 2003-02-14 | Silab Sa | Principe actif riche en isoflavones, son procede d'extraction et ses applications cosmetiques |
FR2828400B1 (fr) * | 2001-08-10 | 2003-11-07 | Oreal | Composition cosmetique ou dermatologique comprenant une association entre de l'igf1 et/ou un compose mimetique de l'igf1, et au moins un retinoide et/ou au moins un derive de retinoide |
FR2834462B1 (fr) * | 2002-01-08 | 2004-03-12 | Silab Sa | Procede de preparation d'un principe actif vegetal, en particulier hydratant et a effet anti-rides, principe actif obtenu, composition et application en cosmetique |
FR2855749B1 (fr) * | 2003-06-03 | 2005-08-19 | Silab Sa | Procede d'obtention d'un principe actif dote de proprietes de photoprotection, principe actif obtenu et compositions l'incluant |
JP2006176481A (ja) * | 2004-12-21 | 2006-07-06 | Tsi:Kk | 化粧料 |
FR2887148B1 (fr) * | 2005-06-17 | 2007-08-24 | Silab Sa | Procede d'obtention d'un principe actif anti-age et principe actif obtenu |
JP2007210915A (ja) * | 2006-02-08 | 2007-08-23 | Kose Corp | 皮膚外用剤 |
FR2897266B1 (fr) * | 2006-02-16 | 2008-05-30 | Limousine D Applic Biolog Dite | Utilisation cosmetique d'un extrait de pichia anomala |
KR100878365B1 (ko) * | 2007-05-14 | 2009-01-15 | 김혜정 | 천연 한방 미용팩 |
CN101815502B (zh) * | 2007-09-04 | 2013-10-09 | 欧莱雅 | 橙皮苷和微生物的组合在影响皮肤的屏障功能中的用途 |
JP2009256270A (ja) * | 2008-04-18 | 2009-11-05 | Maruzen Pharmaceut Co Ltd | インスリン様成長因子−1発現促進剤 |
KR20100090992A (ko) * | 2009-02-09 | 2010-08-18 | 이금희 | 곡물 분말을 함유하는 비누 조성물 및 그의 제조방법 |
EP2110123B1 (fr) * | 2009-03-30 | 2016-03-23 | Shiseido Company, Ltd. | Proliférateur de fibroblaste |
-
2011
- 2011-06-20 FR FR1155401A patent/FR2976490B1/fr active Active
-
2012
- 2012-06-20 WO PCT/FR2012/051388 patent/WO2012175868A2/fr unknown
- 2012-06-20 EP EP12738512.8A patent/EP2720677B1/fr active Active
Non-Patent Citations (1)
Title |
---|
See references of WO2012175868A2 * |
Also Published As
Publication number | Publication date |
---|---|
FR2976490A1 (fr) | 2012-12-21 |
EP2720677B1 (fr) | 2020-12-02 |
WO2012175868A2 (fr) | 2012-12-27 |
WO2012175868A3 (fr) | 2013-02-28 |
FR2976490B1 (fr) | 2013-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012175868A2 (fr) | Utilisation de substances agissant sur l'igf-1 et/ou l'igf-1r pour leur activite anti-age | |
EP2203153A2 (fr) | Utilisation d'un nouvel agent naturel dans des compositions cosmetiques | |
FR2938768A1 (fr) | Utilisation cosmetique d'un extrait de pichia pour restructurer la peau, principe actif, procede d'obtention et compositions | |
WO2015181750A1 (fr) | Utilisation cosmetique d'un polysaccharide sulfate | |
Heinrich et al. | In vivo assessment of ectoin: a randomized, vehicle-controlled clinical trial | |
FR3016521A1 (fr) | Principe actif obtenu a partir de pichia anomala et utilisation pour lutter contre le phenomene d'inflammation chronique de la peau | |
EP2953611A1 (fr) | Utilisation d'une composition comprenant un perséose d'avocat dans la protection des cellules souches épidermiques | |
FR3069164A1 (fr) | Utilisation d'un extrait bacterien pour un traitement cosmetique ou dermatologique notamment hydratant | |
FR2921561A1 (fr) | Composition cosmetique destinee a ameliorer l'etat de peau | |
FR2934779A1 (fr) | Utilisation cosmetique d'un actif issu de ceratonia siliqua, principe actif et procede d'obtention. | |
EP2727579B1 (fr) | Principe actif à application cutanée obtenu à partir de Metschnikowia agaves et utilisations pour améliorer l'état de la peau | |
KR102147482B1 (ko) | 미세조류 오일을 유효성분으로 함유하는 피부노화 개선용 화장료 조성물 | |
FR2902656A1 (fr) | Utilisation cosmetique d'un extrait de withania somnifera | |
FR3097767A1 (fr) | Principe actif obtenu à partir de fleurs deNymphaea alba | |
EP3773430A1 (fr) | Utilisation d'un film sec pour des applications topiques cosmetiques | |
EP1948129B1 (fr) | Procede d'obtention d'un principe actif exhausteur de la resistance mecanique cutanee, principe actif et compositions | |
FR2945209A1 (fr) | Utilisation cosmetique d'un principe actif issu de lens culinaris ou lens esculenta pour lutter contre la dilatation des pores. | |
FR2895906A1 (fr) | Principe actif issu d'annova squamosa, procede d'obtention et utilisation cosmetique a visee anti-age | |
FR2890312A1 (fr) | Procede d'obtention d'un principe actif repulpant, principe actif obtenu et compositions cosmetiques l'incluant | |
FR3040625A1 (fr) | Principe actif cosmetique issu d'helichrysum stoechas et utilisation pour lutter contre le vieillissement de la peau | |
FR3092249A1 (fr) | Principe actif cosmetique issu de tourteau de graines de simmondsia chinensis et utilisations cosmetiques | |
EP4043005B1 (fr) | Composition cosmétique comprenant un hydrolysat de levure | |
FR2979541A1 (fr) | Principe actif issu de torulaspora delbrueckii et utilisation cosmetique pour ameliorer et/ou reparer la fonction barriere de la peau | |
FR2982152A1 (fr) | Polysaccharides sulfates agent d'hydratation de la peau | |
FR3000389A1 (fr) | Procede cosmetique de stimulation de la synthese d'aquaporine 8 par application cutanee d'une composition cosmetique comprenant un extrait de jania rubens. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20131219 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20160317 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602012073497 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0008970000 Ipc: A61K0008990000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 8/99 20170101AFI20200602BHEP Ipc: A61Q 19/08 20060101ALI20200602BHEP |
|
INTG | Intention to grant announced |
Effective date: 20200629 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SOCIETE INDUSTRIELLE LIMOUSINE D'APPLICATION BIOLOGIQUE |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1340104 Country of ref document: AT Kind code of ref document: T Effective date: 20201215 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012073497 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: FRENCH |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210303 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210302 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20201202 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1340104 Country of ref document: AT Kind code of ref document: T Effective date: 20201202 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210302 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210405 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012073497 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210402 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 |
|
26N | No opposition filed |
Effective date: 20210903 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20210620 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210620 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210630 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210620 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210620 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210402 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20120620 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240531 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240626 Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 |